sorafenib
Tislelizumab Vies for First-Line Designation in Treatment of Advanced HCC
The checkpoint inhibitor tislelizumab might reasonably be considered a better choice for hepatocellular carcinoma ...
NOVEMBER 20, 2023
Better Outcomes, No Reduced Safety When Sorafenib Preceded by Stereotactic Body Radiation Therapy for HCC
Administering stereotactic body radiation therapy (SBRT) prior to sorafenib significantly improves overall and ...
FEBRUARY 15, 2023
Tremelimumab/Durvalumab Combo Promising for Unresectable HCC
Combining a single priming dose of tremelimumab and durvalumab significantly improved overall survival in the ...
FEBRUARY 10, 2022
FDA Approves HCC Indication for Lenvima
The FDA approved a new indication for Lenvima for first-line treatment of patients with unresectable hepatocellular ...
AUGUST 20, 2018
Sorafenib and Sunitinib Similar to Placebo in High-Risk RCC Patients
Neither sorafenib nor sunitinib appeared to be more effective than placebo at improving disease-free survival in ...
APRIL 13, 2017
Novel Second-Line Therapies Offer Benefit in HCC
Copenhagen, Denmark—As a second-line treatment for hepatocellular carcinoma (HCC) after progression on ...
JANUARY 26, 2017
Adjuvant Sorafenib, Sunitinib Don’t Prevent RCC Recurrence
In resected local kidney cancer at high risk for recurrence, sorafenib or sunitinib did not increase survival
MAY 24, 2016